

19.9. However, the MCC has registered both AZT and NVP as appropriate medicines to be used in the treatment of HIV and for use in mother-to-child transmission prevention of HIV/AIDS. The MCC has registered these medicines on the basis of a number of studies submitted to the MCC. The MCC has been extremely cautious in its registration of AZT and NVP for mother-to-child transmission prevention and the package inserts of both medicines are a reflection of the conditions associated with their use. In this respect, ASASA must consult with the MCC.